You're Taking Omega-3s and Still Deficient. Your Genes May Be Why.

FADS1 encodes delta-5 desaturase, an enzyme that performs the final conversion step in the pathway from ALA to EPA. This enzyme takes EPA precursors and converts them into the longer-chain, more potent form that your brain, heart, and immune system actually use. It’s a critical bottleneck.

The common variant rs174537, carried by roughly 30-40% of the population, reduces delta-5 desaturase activity. People with this variant have a measurably harder time converting ALA into EPA, meaning dietary omega-3 sources are far less effective for raising EPA levels. Your body can make the attempt, but it does so at a fraction of the normal rate. The result is that your tissues stay deprived even when you are eating omega-3-rich foods.

You feel this as poor recovery from exercise, persistent joint stiffness, difficulty with mood regulation, and brain fog that doesn’t resolve with sleep. You may also notice that inflammation markers stay elevated despite your best dietary efforts. Your cells are hungry for EPA, but the conversion pipeline is too slow to satisfy that hunger.

FADS2 encodes delta-6 desaturase, the enzyme that catalyzes the very first conversion step in the omega-3 pathway. ALA (from flax, chia, walnuts) cannot move forward in the pipeline without delta-6 desaturase breaking it down. This enzyme is the gateway. If it’s slow, nothing downstream happens efficiently.

The variant rs1535, present in roughly 30-40% of the population, significantly reduces delta-6 desaturase activity. People carrying this variant have a slower pathway from plant-based omega-3 precursors to EPA, which means they need 3-5 times more dietary ALA to achieve the same EPA status as someone without the variant. The conversion simply doesn’t happen at the normal rate. You can eat walnuts, flax, and chia seeds every day and still remain depleted because the first step in the conversion is too slow to keep up with demand.

You experience this as stubborn inflammation, especially in joints. Your mood may feel fragile. Your cognitive clarity is lower than it should be. You may have tried fish oil and seen minimal improvement because the downstream capacity to utilize it is limited by your FADS2 enzyme. The bottleneck is real.

PPARG encodes peroxisome proliferator-activated receptor gamma, a nuclear receptor that acts as a master control switch for fat cell metabolism and inflammation. PPARG tells your fat cells how to behave, whether to store energy or burn it, whether to signal inflammation or resolution. EPA works partly by activating PPARG signaling. If your PPARG function is compromised, EPA becomes less effective even if you have adequate levels.

Common PPARG variants reduce the gene’s capacity to regulate lipid metabolism and inflammatory signaling. People with PPARG variants struggle with fat cell inflammation and systemic metabolic inflammation, which increases the cellular demand for EPA. Your tissues need more EPA to counteract the inflammatory state that your genetics are predisposing you toward. You can have adequate dietary EPA intake and still be functionally depleted because your cells are burning through it faster than normal to manage inflammation.

You notice this as low-grade, persistent inflammation in your joints and gut. Your weight management is harder than it should be despite reasonable dietary compliance. Your recovery from exercise is slow. Your lipid markers may be suboptimal. You’re dealing with metabolic inflammation driven by your PPARG genetics, and standard omega-3 doses don’t address it because the underlying problem is PPARG function, not just EPA availability.

APOE encodes apolipoprotein E, the primary lipid transport protein in your brain and bloodstream. APOE determines how efficiently your body packages and moves EPA, cholesterol, and other lipids from your gut, liver, and bloodstream into your cells where they’re needed. It’s the delivery system. If the delivery system is inefficient, EPA supplementation has nowhere to go.

The three main APOE variants (E2, E3, E4) have dramatically different effects on lipid metabolism. Roughly 25-30% of the population carries the APOE4 allele, which is associated with less efficient lipid uptake and a higher risk of lipid accumulation in the brain. People with APOE4 have measurably lower tissue EPA levels despite similar dietary intake, because their cells are less efficient at importing and utilizing omega-3 fatty acids. Your bloodwork may show adequate serum EPA, but your actual tissue EPA availability is lower. The EPA is in your blood but not getting into your cells where it matters.

You experience this as cognitive decline or persistent brain fog, poor mood resilience, joint pain that doesn’t resolve with standard EPA doses, and cardiovascular markers that remain suboptimal. You may have excellent bloodwork on paper but feel functionally depleted. The problem is not absorption or intake. It’s cellular utilization.

MTHFR encodes methylenetetrahydrofolate reductase, the enzyme that converts folate into its active form, 5-methyltetrahydrofolate. This active form fuels the methylation cycle, which produces the energy cofactors that every cell in your body depends on. Methylation is required for producing and maintaining the phospholipid membranes that hold omega-3 fatty acids in your cell walls. If MTHFR is slow, your methylation cycle is compromised, and your cells literally cannot retain EPA.

The C677T variant, carried by roughly 40% of the population with European ancestry, reduces MTHFR enzyme efficiency by 40-70%. People with the C677T variant have functional folate deficiency, which impairs methylation, which means their cell membranes have reduced capacity to incorporate and retain EPA. You can supplement EPA, but if your methylation cycle is broken, your cells cannot properly integrate it into phospholipid membranes. The EPA passes through and gets wasted. Your methylation machinery is also running slow, which increases systemic inflammation and reduces your cells’ ability to produce the energy they need to manage that inflammation.

You feel this as persistent fatigue, brain fog, mood instability, and inflammation markers that stay elevated despite aggressive EPA supplementation. You recover slowly from exercise. Your energy crashes easily. Your joints ache. The problem is not just EPA. It’s that your methylation cycle is too slow to fuel the cellular processes that EPA is supposed to support.

VDR encodes the vitamin D receptor, a nuclear receptor that sits on the surface of nearly every cell in your body and translates vitamin D signals into cellular action. Vitamin D is a signaling molecule, not just a nutrient. The VDR is the lock that vitamin D turns. If your VDR function is compromised, vitamin D cannot do its job, and your immune system and inflammatory responses become dysregulated.

Common VDR variants (BsmI, FokI, TaqI), present in roughly 30-50% of the population, reduce the efficiency of vitamin D signaling at the cellular level. People with VDR variants have functional vitamin D deficiency even when serum vitamin D levels look adequate on bloodwork, because their cells cannot translate vitamin D signals into anti-inflammatory action. Vitamin D is supposed to suppress inflammatory signaling. If your VDR is slow, that suppression doesn’t happen effectively. Your immune system stays in a primed, inflamed state. EPA is an anti-inflammatory nutrient, but it cannot fully compensate for the inflammatory tone that VDR dysfunction is creating.

You notice this as persistent low-grade infection susceptibility, slow healing from wounds or illness, difficulty managing inflammation despite adequate EPA intake, and immune responses that are either too strong (autoimmunity risk) or too weak (infection risk). Your vitamin D supplementation doesn’t seem to move the needle. Your inflammation markers stay elevated. The problem is VDR function, not vitamin D intake.